ALD |
Alcoholic liver disease |
ALF |
Acute liver failure |
ALP |
Alkaline phosphatase |
ALT |
Alanine aminotransferase |
APAP |
N-acetyl-para-aminophenol |
AST |
Aspartate aminotransferase |
ATP |
Adenosine triphosphate |
CMV |
Cytomegalovirus. |
CAM |
Causality assessment method |
CK |
Cytokeratin |
ccCK |
Caspase-cleaved CytoKeratin |
CYP |
Cytochrome P450 |
Cys |
Cysteine |
DILI |
Drug induced liver injury |
EBV |
Epstein Barr virus |
eDISH |
Evaluation of Drug-Induced Serious Hepatotoxicity |
EMA |
European Medicines Agency |
FDA |
Food and Drug Administration in Washington, DC |
GLDH |
Glutamate dehydrogenase |
GSH |
Glutathione |
GST |
Glutathione S-transferase |
HAV |
Hepatitis A virus |
HBV |
Hepatitis B virus |
HCV |
Hepatitis C virus |
HEV |
Hepatitis E virus |
HILI |
Herb induced liver injury |
HLA |
Human leucocyte antigen |
HMGB |
High Mobility Group Box (protein) |
HSOS |
Hepatic sinusoidal obstructions syndrome. |
IMI |
Innovative Medicines Initiative |
INH |
Isonicotinic acid hydrazide |
LTs |
Liver tests |
MCSFR-1 |
Macrophage colony-stimulating factor receptor-1 |
microRNA |
Microarray RNA |
NAFLD |
Non-alcoholic fatty liver disease |
NAPQI |
N-acetyl-para-quinone imine |
NASH |
Non-alcoholic steatohepatitis |
MCSFR |
Macrophage colony stimulating factor receptor |
PAs |
Pyrrolizidine alkaloids |
PCR |
Polymerase chain reaction. |
R |
Ratio |
ROS |
Reactive oxygen species |
RUCAM |
Roussel Uclaf Causality Assessment Method |
SDH |
Sorbitol dehydrogenase |
SAFE-T |
Safer and Faster Evidence-based Translation |
SULT |
Sulfotransferase |
TBIL |
Total bilirubin |
TCM |
Traditional Chinese Medicine |
UGT |
UDP-glucuronosyltransferases |
ULN |
Upper limit of normal (range) |
VZV |
Varicella zoster virus |